Everolimus is a potent inhibitor of activated hepatic stellate cell functions in vitro and in vivo, while demonstrating anti-angiogenic activities

Clinical Science

Volumn 126, Issue 11, 2014, Pages 775-784

  Piguet, Anne Christine ^a   Majumder, Syamantak ^b   Maheshwari, Uma ^b   Manjunathan, Reji ^b   Saran, Uttara ^b   Chatterjee, Suvro ^b   Dufour, Jean François ^a,c  

^a UNIVERSITY OF BERN   (Switzerland)

^b ANNA UNIVERSITY   (India)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Angiogenesis; Everolimus; Hepatic stellate cell; Hepatocellular carcinoma; Mammalian target of rapamycin (mTOR)

Indexed keywords

ACTINS; ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; COLLAGEN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPATIC STELLATE CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MUSCLE, SMOOTH; MYOFIBROBLASTS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, WISTAR; SIROLIMUS;

EID: 84894504866     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20130081     Document Type: Article

References (37)

1. Sato, M., Suzuki, S. and Senoo, H. (2003) Hepatic stellate cells: unique characteristics in cell biology and phenotype. Cell Struct. Funct. 28, 105-112.
2. Antonelli-Orlidge, A., Saunders, K. B., Smith, S. R. and D'Amore, P. A. (1989) An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes. Proc. Natl. Acad. Sci. U.S.A. 86, 4544-4548.
3. Lee, J. S., Kang Decker, N., Chatterjee, S., Yao, J., Friedman, S. and Shah, V. (2005) Mechanisms of nitric oxide interplay with Rho GTPase family members in modulation of actin membrane dynamics in pericytes and fibroblasts. Am. J. Pathol. 166, 1861-1870.
4. Flamme, I., Frolich, T. and Risau, W. (1997) Molecular mechanisms of vasculogenesis and embryonic angiogenesis. J. Cell. Physiol. 173, 206-210.
5. Kramer, S., Wang-Rosenke, Y., Scholl, V., Binder, E., Loof, T., Khadzhynov, D., Kawachi, H., Shimizu, F., Diekmann, F., Budde, K. et al. (2008) Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat. Am. J. Physiol. Renal Physiol. 294, F440-F449.
6. Semela, D., Piguet, A. C., Kolev, M., Schmitter, K., Hlushchuk, R., Djonov, V., Stoupis, C. and Dufour, J. F. (2007) Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J. Hepatol. 46, 840-848.
7. Patsenker, E., Schneider, V., Ledermann, M., Saegesser, H., Dorn, C., Hellerbrand, C. and Stickel, F. (2011) Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. J. Hepatol. 55, 388-398.
8. Xu, L., Hui, A. Y., Albanis, E., Arthur, M. J., O'Byrne, S. M., Blaner, W. S., Mukherjee, P., Friedman, S. L. and Eng, F. J. (2005) Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 54, 142-151.
9. Van de Bovenkamp, M., Groothuis, G. M., Meijer, D. K. and Olinga, P. (2007) Liver fibrosis in vitro: cell culture models and precision-cut liver slices. Toxicol. In Vitro 21, 545-557.
10. Perri, R. E., Langer, D. A., Chatterjee, S., Gibbons, S. J., Gadgil, J., Cao, S., Farrugia, G. and Shah, V. H. (2006) Defects in cGMP-PKG pathway contribute to impaired NO-dependent responses in hepatic stellate cells upon activation. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G535-G542.
11. Majumder, S., Piguet, A. C., Dufour, J. F. and Chatterjee, S. (2013) Study of the cellular mechanism of Sunitinib mediated inactivation of activated hepatic stellate cells and its implications in angiogenesis. Eur. J. Pharmacol. 705, 86-95.
12. Geerts, A., Vrijsen, R., Rauterberg, J., Burt, A., Schellinck, P. and Wisse, E. (1989) In vitro differentiation of fat-storing cells parallels marked increase of collagen synthesis and secretion. J. Hepatol. 9, 59-68.
13. Donovan, D., Brown, N. J., Bishop, E. T. and Lewis, C. E. (2001) Comparison of three in vitro human 'angiogenesis' assays with capillaries formed in vivo. Angiogenesis 4, 113-121.
14. Niemisto, A., Dunmire, V., Yli-Harja, O., Zhang, W. and Shmulevich, I. (2005) Analysis of angiogenesis using in vitro experiments and stochastic growth models. Phys. Rev. E Stat. Nonlin. Soft Matter Phys. 72, 062902.
15. Beuvink, I., Boulay, A., Fumagalli, S., Zilbermann, F., Ruetz, S., O'Reilly, T., Natt, F., Hall, J., Lane, H. A. and Thomas, G. (2005) The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120, 747-759.
16. Rahimi, R. A., Andrianifahanana, M., Wilkes, M. C., Edens, M., Kottom, T. J., Blenis, J. and Leof, E. B. (2009) Distinct roles for mammalian target of rapamycin complexes in the fibroblast response to transforming growth factor-β. Cancer Res. 69, 84-93.
17. Biecker, E., De Gottardi, A., Neef, M., Unternahrer, M., Schneider, V., Ledermann, M., Sagesser, H., Shaw, S. and Reichen, J. (2005) Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis: analysis of the underlying mechanisms. J. Pharmacol. Exp. Ther. 313, 952-961.
18. Gabele, E., Reif, S., Tsukada, S., Bataller, R., Yata, Y., Morris, T., Schrum, L. W., Brenner, D. A. and Rippe, R. A. (2005) The role of p70S6K in hepatic stellate cell collagen gene expression and cell proliferation. J. Biol. Chem. 280, 13374-13382.
19. Le Pabic, H., L'Helgoualc'h, A., Coutant, A., Wewer, U. M., Baffet, G., Clement, B. and Theret, N. (2005) Involvement of the serine/threonine p70S6 kinase in TGF-β1-induced ADAM12 expression in cultured human hepatic stellate cells. J. Hepatol. 43, 1038-1044.
20. Lee, S. J., Yang, E. K. and Kim, S. G. (2006) Peroxisome proliferator-activated receptor-γ and retinoic acid X receptor alpha represses the TGFβ1 gene via PTEN-mediated p70 ribosomal S6 kinase-1 inhibition: role for Zf9 dephosphorylation. Mol. Pharmacol. 70, 415-425.
21. Liu, Y., Wen, X. M., Lui, E. L., Friedman, S. L., Cui, W., Ho, N. P., Li, L., Ye, T., Fan, S. T. and Zhang, H. (2009) Therapeutic targeting of the PDGF and TGF-β-signaling pathways in hepatic stellate cells by PTK787/ZK22258. Lab. Invest. 89, 1152-1160.
22. Mann, D. A. and Smart, D. E. (2002) Transcriptional regulation of hepatic stellate cell activation. Gut 50, 891-896.
23. Mann, J., Oakley, F., Akiboye, F., Elsharkawy, A., Thorne, A. W. and Mann, D. A. (2007) Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis. Cell Death Differ. 14, 275-285.
24. Horowitz, A., Menice, C. B., Laporte, R. and Morgan, K. G. (1996) Mechanisms of smooth muscle contraction. Physiol. Rev. 76, 967-1003.
25. Lindert, S., Wickert, L., Sawitza, I., Wiercinska, E., Gressner, A. M., Dooley, S. and Breitkopf, K. (2005) Transdifferentiation-dependent expression of α-SMA in hepatic stellate cells does not involve TGF-β pathways leading to coinduction of collagen type I and thrombospondin-2. Matrix Biol. 24, 198-207.
26. Lockwood, D. S. R. and Gotley, D. C. (2005) Interaction of tumour with host stroma in hepatocellular carcinoma. In Integration/Interaction of Oncologic Growth (Meadows, G. G., ed.), pp. 165-176, Springer, Amsterdam.
27. Foster, K. G. and Fingar, D. C. (2010) Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J. Biol. Chem. 285, 14071-14077.
28. Guertin, D. A. and Sabatini, D. M. (2009) The pharmacology of mTOR inhibition. Sci. Signal. 2, pe24.
29. Julien, L. A., Carriere, A., Moreau, J. and Roux, P. P. (2010) mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol. Cell. Biol. 30, 908-921.
30. Kuper, M. A., Scholzl, N., Traub, F., Mayer, P., Weinreich, J., Coerper, S., Steurer, W., Konigsrainer, A. and Beckert, S. (2011) Everolimus interferes with the inflammatory phase of healing in experimental colonic anastomoses. J. Surg. Res. 167, 158-165.
31. Tugues, S., Fernandez-Varo, G., Munoz-Luque, J., Ros, J., Arroyo, V., Rodes, J., Friedman, S. L., Carmeliet, P., Jimenez, W. and Morales-Ruiz, M. (2007) Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 46, 1919-1926.
32. Frost, P., Moatamed, F., Hoang, B., Shi, Y., Gera, J., Yan, H., Gibbons, J. and Lichtenstein, A. (2004) In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood 104, 4181-4187.
33. Honer, M., Ebenhan, T., Allegrini, P. R., Ametamey, S. M., Becquet, M., Cannet, C., Lane, H. A., O'Reilly, T. M., Schubiger, P. A., Sticker-Jantscheff, M. et al. (2010) Anti-angiogenic/vascular effects of the mTOR inhibitor everolimus are not detectable by FDG/FLT-PET. Transl. Oncol. 3, 264-275.
34. Del Bufalo, D., Ciuffreda, L., Trisciuoglio, D., Desideri, M., Cognetti, F., Zupi, G. and Milella, M. (2006) Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res. 66, 5549-5554.
35. Bosch, J. (2007) Vascular deterioration in cirrhosis: the big picture. J. Clin. Gastroenterol. 41, S247-S253.
36. Muhanna, N., Doron, S., Abu-Tair, L., Zayyad, H., Mahamid, M., Amer, J. and Safadi, R. (2013) Early fibrosis inhibits hepatocellular carcinoma mediated by free radical effects. Mitochondrion 13, 391-398.
37. Svegliati-Baroni, G., Faraci, G., Fabris, L., Saccomanno, S., Cadamuro, M., Pierantonelli, I., Trozzi, L., Bugianesi, E., Guido, M., Strazzabosco, M. et al. (2011) Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C. Gut 60, 108-115.